Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Remarks:
combined repeated dose and reproduction / developmental screening
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: No GLP defined
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
1996

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
1,3-dichloro-4-nitrobenzene
EC Number:
210-248-3
EC Name:
1,3-dichloro-4-nitrobenzene
Cas Number:
611-06-3
Molecular formula:
C6H3Cl2NO2
IUPAC Name:
2,4-dichloro-1-nitrobenzene
Details on test material:
Purity: 98.0 %

Test animals

Species:
rat
Strain:
Crj: CD(SD)
Sex:
male/female

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
Males, 45 days
Females, from 14 days before mating to day 3 of lactation
Frequency of treatment:
no data
Doses / concentrations
Remarks:
Doses / Concentrations:
0 (Vehicle), 8, 40, 200 mg/kg/day
Basis:
other: vehicle: corn oil
No. of animals per sex per dose:
Males: 12; Females: 12/group
Control animals:
yes

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
effects observed, treatment-related
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
effects observed, treatment-related
Behaviour (functional findings):
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
effects observed, treatment-related

Effect levels

Dose descriptor:
NOEL
Effect level:
< 8 mg/kg bw/day (nominal)
Sex:
male/female

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

There were no abnormal clinical signs attributable to the administration of the test substance, although, one female rat given 200 mg/kg died during delivery. The body weight gain of females given 200 mg/kg was lower than that of the controls during the gestation period.

Hematological examination revealed decreases in red blood cells in males given 8 mg/kg or more, decreases in hematocrit and hemoglobin, increases in reticulocytes, and slight anemia in males given 40 and 200 mg/kg. Blood clinical examination revealed increases in total protein, albumin and gamma-GTP and decreases in creatinine in males given 40 and 200 mg/kg. Total bilirubin and the A/G ratio were increased in males given 200 mg/kg. Absolute and relative liver and kidney weights showed increase or a tendency for increase in both sexes given 200 mg/kg. necropsy revealed enlargement of the liver in both sexes given 200 mg/kg, and enlargement of kidneys in males given 200 mg/kg. Other treatment-related gross findings included atrophy of the thymus and enlargement of the adrenal glands in treated females.

Histopathological examination revealed swelling and single cell necrosis of liver cells in both sexes given 200 mg/kg. Moreover, mitosis of liver cells were observed in males given 200 mg/kg. The slight increase in the incidence of hyaline droplets of the renal tubules in males and basophilic change of the renal tubules in females, both given 200 mg/kg, were also noted in a few females given 8 mg/kg or more, and necrosis of the renal tubules was observed in a few females given 40 and 200 mg/kg. A variety of lesions including a moderate degree of pigment deposit in the spleen, atrophy of the thymus, swelling of the liver cells, ulcer action in the stomach, duodenum and large intestine, single liver cell necrosis and fibrosis of the renal tubular epithelium, were observed in females that delivered all stillborn pups and in females where all pups died, in the group given 200 mg/kg. Counting of numbers of spermatogenic cells at stage VIII in the testes from control males and males given 200 mg/kg revealed no treatment-related effects.

Applicant's summary and conclusion

Executive summary:

The test substance was studied for oral toxicity in an OECD combined repeat dose and reproductive/developmental toxicity screening test at doses of 0, 8, 40 and 200 mg/kg/day. With regard to repeat dose toxicity, one female rat given 200 mg/kg died during delivery. Body weight gain of females given 200 mg/kg was lower than that of controls during the gestation period. hematological examination showed decreases of red blood cells in males given 8 mg/kg or more, as well as decreases of hematocrit and hemoglobin, increases of reticulocytes, and slight anemia in males given 40 and 200 mg/kg. Blood chemical examination revealed increases in total protein, albumin and y-GTP and decreases in creatinine in males given 40 and 200 mg/kg. Increases in total bilirubin and A/G ratio were also observed in males given 200 mg/kg. Absolute and relative weights of the liver and kidneys showed increases or a tendency for increase in both sexes given 200 mg/kg and mg/kg. As gross findings, enlargement of the liver was observed in both sexes given 200 mg/kg and enlargement of the kidneys in males given 200 mg/kg. Histopathologial examination revealed swelling and single cell necrosis of liver cells in both sexes given 200 mg/kg. Moreover, mitosis of liver cells were observed in the liver of males given 200 mg/kg. The slight increase in the incidence of hyaline droplets of renal tubules in males and basophilic change of the renal tubules in females, both given 200 mg/kg, were also noted in a few females given 8 mg/kg or more, and necrosis of the renal tubules was observed in a few females given 40 and 200 mg/kg.

The author declared 8 mg/kg as LOEL, because slight effects on red blood cells in male rats (red blood counts: control 7.98 mg/kg; 8 mg/kg= 7.79 mg/kg) and histopathology were observed, but the effects on red blood cells were isolated effects and no other effects were observed.

Basophile changes (contol group= 1 rat; 8 mg/kg= 2 rats; 40 mg/kg= 1 rat; 200 mg/kg 5 rats) The results were not dose related and no signifficant effect was seen in the 8 mg/kg group of female rats

Because the effects were not seen as advers the LOEL = NOAEL of 8 mg/kg.